Ann-Christine Sundell, born in 1964, has extensive experience from leading positions and board assignments in medtech and diagnostics, including global market expansion, product development and the establishment of national screening programs. She has had a long and successful career, including in PerkinElmer, where she was responsible for the Genetic Screening division, a rapidly growing business unit in a globally leading position. She is currently a board member of Medix Biochemica, Actim, Biocartis, Revenio and Immunovia AB (publ).

Other proposals from the Nomination Committee will be presented in the notice to attend the 2022 Annual General Meeting.